Severity of Fontan-Associated Liver Disease Correlates with Fontan Hemodynamics

被引:0
|
作者
Anastasia Schleiger
Madeleine Salzmann
Peter Kramer
Friederike Danne
Stephan Schubert
Christian Bassir
Tobias Müller
Hans-Peter Müller
Felix Berger
Stanislav Ovroutski
机构
[1] German Heart Center Berlin,Department of Congenital Heart Disease/Pediatric Cardiology
[2] Charité-Universitätsmedizin Berlin,Department of Pediatric Radiology
[3] Charité Universitätsmedizin Berlin,Department of Gastroenterology and Hepatology
[4] DZHK (German Center for Cardiovascular Research),Division of Cardiology, Department of Pediatrics
[5] Charité Universitätsmedizin Berlin,undefined
来源
Pediatric Cardiology | 2020年 / 41卷
关键词
Fontan-associated liver disease; Liver cirrhosis; Fontan surveillance; Fontan hemodynamics; Risk factors for FALD;
D O I
暂无
中图分类号
学科分类号
摘要
Fontan-palliated patients are at risk for the development of Fontan-associated liver disease (FALD). In this study, we performed a detailed hemodynamic and hepatic assessment to analyze the incidence and spectrum of FALD and its association with patients' hemodynamics. From 2017 to 2019, 145 patients underwent a detailed, age-adjusted hepatic examination including laboratory analysis (FibroTest®, n = 101), liver ultrasound (n = 117) and transient elastography (FibroScan®, n = 61). The median patient age was 16.0 years [IQR 14.2], and the median duration of the Fontan circulation was 10.3 years [IQR 14.7]. Hemodynamic assessment was performed using echocardiography, cardiopulmonary exercise capacity testing and cardiac catheterization. Liver ultrasound revealed hepatic parenchymal changes in 83 patients (70.9%). Severe liver cirrhosis was detectable in 20 patients (17.1%). Median liver stiffness measured by FibroScan® was 27.7 kPa [IQR 14.5], and the median Fibrotest® score was 0.5 [IQR 0.3], corresponding to fibrosis stage ≥ 2. Liver stiffness values and Fibrotest® scores correlated significantly with Fontan duration (P1 = 0.013, P2 = 0.012). Exercise performance was significantly impaired in patients with severe liver cirrhosis (P = 0.003). Pulmonary artery pressure and end-diastolic pressure were highly elevated in cirrhotic patients (P1 = 0.008, P2 = 0.003). Multivariable risk factor analysis revealed Fontan duration to be a major risk factor for the development of FALD (P < 0.001, OR 0.77, CI 0.68–0.87). In the majority of patients, hepatic abnormalities suggestive of FALD were detectable by liver ultrasound, transient elastography and laboratory analysis. The severity of FALD correlated significantly with Fontan duration and impaired Fontan hemodynamics. A detailed hepatic assessment is indispensable for long-term surveillance of Fontan patients.
引用
收藏
页码:736 / 746
页数:10
相关论文
共 50 条
  • [41] Fontan-Associated Liver Disease Screening, Management, and Transplant Considerations
    Emamaullee, Juliet
    Zaidi, Ali N.
    Schiano, Thomas
    Kahn, Jeffrey
    Valentino, Pamela L.
    Hofer, Ryan E.
    Taner, Timucin
    Wald, Joyce W.
    Olthoff, Kim M.
    Bucuvalas, John
    Fischer, Ryan
    CIRCULATION, 2020, 142 (06) : 591 - 604
  • [42] Non-invasive biomarkers of Fontan-associated liver disease
    Emamaullee, Juliet
    Khan, Sara
    Weaver, Carly
    Goldbeck, Cameron
    Yanni, George
    Kohli, Rohit
    Genyk, Yuri
    Zhou, Shengmei
    Shillingford, Nick
    Sullivan, Patrick M.
    Takao, Cheryl
    Detterich, Jon
    Kantor, Paul F.
    Cleveland, John D.
    Herrington, Cynthia
    Kumar, S. Ram
    Starnes, Vaughn
    Badran, Sarah
    Patel, Neil D.
    JHEP REPORTS, 2021, 3 (06)
  • [43] Characteristics of Liver Tumor Arising from Fontan-Associated Liver Disease
    Sagawa, Takaomi
    Kogiso, Tomomi
    Kodama, Kazuhisa
    Taniai, Makiko
    Tokushige, Katsutoshi
    HEPATOLOGY, 2018, 68 : 529A - 529A
  • [44] Screening for Fontan-associated liver disease: are we doing enough?
    Tsoi, V.
    Mitropoulou, P.
    Chatterjee, K.
    Lwin, M.
    Salmon, A.
    Smith, L.
    Fitzsimmons, S.
    Kyi, N.
    Carroll, A.
    EUROPEAN HEART JOURNAL, 2021, 42 : 1888 - 1888
  • [45] Fontan-Associated Dyslipidemia
    Lubert, Adam M.
    Alsaied, Tarek
    Palermo, Joseph J.
    Anwar, Nadeem
    Urbina, Elaine M.
    Brown, Nicole M.
    Alexander, Craig
    Almeneisi, Hassan
    Wu, Fred
    Leventhal, Andrew R.
    Aldweib, Nael
    Mendelson, Michael
    Opotowsky, Alexander R.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (07):
  • [46] SCREENING FOR AND MONITORING FONTAN-ASSOCIATED LIVER DISEASE IN A TERTIARY CENTRE
    Mitropoulou, Panagiota
    Carroll, Aisling
    Fitzsimmons, Samantha
    Smith, Lindsay
    Ramgopal, Balasubramanian
    Kyi, Nang
    HEART, 2023, 109 : A19 - A21
  • [47] Development of Cirrhosis and Portal Hypertension in Fontan-Associated Liver Disease
    Zhang, Hao Chi
    Tung, Poyee
    Machicao, Victor I.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S1263 - S1263
  • [48] Non-invasive Investigations for the Diagnosis of Fontan-Associated Liver Disease in Pediatric and Adult Fontan Patients
    Fidai, Amyna
    Dallaire, Frederic
    Alvarez, Nanette
    Balon, Yvonne
    Clegg, Robin
    Connelly, Michael
    Dicke, Frank
    Fruitman, Deborah
    Harder, Joyce
    Myers, Kimberley
    Patton, David J.
    Prieur, Tim
    Vorhies, Erika
    Myers, Robert P.
    Martin, Steven R.
    Greenway, Steven C.
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2017, 4
  • [49] ARE FONTAN HEMODYNAMICS PREDICTIVE OF FUTURE LIVER DISEASE IN FONTAN PATIENTS?
    Trusty, Phillip
    Wei, Zhenglun Alan
    Rychik, Jack
    Graham, Alexa
    Russo, Pierre A.
    Surrey, Lea F.
    Goldberg, David
    Yoganathan, Ajit
    Fogel, Mark
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 581 - 581
  • [50] Molecular Profile of Malignant Liver Tumors in the Setting of Fontan-Associated Liver Disease
    Francalanci, Paola
    Giovannoni, Isabella
    Gagliardi, Maria Giulia
    Palmieri, Rosalinda
    Spada, Marco
    Maggiore, Giuseppe
    Monti, Lidia
    Castellano, Aurora
    Giustiniani, Maria Cristina
    Barresi, Sabina
    Pietrobattista, Andrea
    Alaggio, Rita
    LABORATORY INVESTIGATION, 2023, 103 (03) : S1355 - S1356